Printer Friendly

ADVANCED BIOTHERAPY CONCEPTS SIGNS AGREEMENT WITH UNIV. OF NEBRASKA MEDICAL CENTER TO COLLABORATE IN TESTING NEW AIDS TREATMENT

 ROCKVILLE, Md., Feb. 10 /PRNewswire/ -- Advanced Biotherapy Concepts, Inc. (OTC Bulletin Board: ADVB), announced today that it has signed an agreement with the University of Nebraska Medical Center to conduct clinical testing of the company's patented treatment for AIDS.
 The main purpose of these trials is to test the safety of the company's extracorporeal device using an immunosorbent column to remove from the patient's blood certain substances thought to play a major role in the pathogenesis of AIDS. Unlike most other therapies, this approach is directed at restoration of the immune system destroyed in AIDS. Later the company plans to test the treatment on patients with different autoimmune diseases.
 The team at the University of Nebraska Medical Center (UNMC) is headed by Drs. Howard E. Gendelman and Susan Swindells. Gendelman, a professor of medicine, pathology and microbiology at UNMC, is one of the leading authorities on cytokines and the human immunodefiency virus, the virus causing AIDS. Swindells is the chief of the HIV-Clinical program at UNMC.
 -0- 2/10/93
 /CONTACT: Jeanne Kelly of Advanced Biotherapy Concepts, Inc., 301-770-7285/
 (ADVB)


CO: Advanced Biotherapy Concepts, Inc.; University of Nebraska
 Medical Center ST: Maryland, Nebraska IN: MTC SU:


KD -- DC024 -- 5275 02/10/93 15:08 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1993
Words:205
Previous Article:TAX FILING ALTERNATIVES GROW IN POPULARITY
Next Article:HUGHES NETWORK SYSTEMS CALLS FOR STRONGER POSITION BY U.S. GOVERNMENT TO PROMOTE WORLDWIDE COMPETITIVENESS OF U.S. DIGITAL CELLULAR/PCS INDUSTRY
Topics:


Related Articles
INITIAL CLINICAL RESULTS FOR NEW AIDS TREATMENT REPORTED
COMPANY BEGINS CLINICAL STUDIES IN RUSSIA FOR NEW TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER AUTOIMMUNE DISEASES
Company Completes Human Clinical Trials in Russia for Treatment of Rheumatoid Arthritis
Company Completes Human Clinical Trials in Russia for Treatment of Rheumatoid Arthritis
Company Announces Collaboration with GroupMed CRO for the Funding and Management of Clinical Trials in Mexico for Rheumatoid Arthritis
BD Applauds PEPFAR's Broadened Emphasis on Strengthening Health Systems.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters